Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03813875
Other study ID # 2017-12-024BC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 12, 2019
Est. completion date May 25, 2022

Study information

Verified date July 2022
Source Taipei Veterans General Hospital, Taiwan
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Demand for anesthesiologists outside the operating rooms is increasing. Surgeons, radiologists, endoscopists and other interventionists are performing procedures with greater complexity, sometimes accompanied by greater pain and therefore require some sedation. This growing need place a pivotal role on careful handling the delivered drugs. Specifically, the investigators wish to know how different classes of drugs interact in order for us to titrate the effects more precisely. Early studies used isobolograms and concentration effect curves as their tools but these methods are limited and incapable of making continuous bedside monitoring. Researchers integrated these methodologies mathematically and developed response surface models. It's becoming a very convenient tool to assess drug interactions. Drug interactions are visualized with a three dimensional graph, or a surface. Users will only need the calculated drug concentrations and a predicted loss of response probability will be given after a model is built. The process of model construction is complex and time demanding process. Our team has successfully built a dual-drug model for midazolam and alfentanil and several works have been published in renowned anesthesia journals. Dual-drug models are simple but their use is very limited. The investigators often use more than two drugs during practice and a three-drug model will be a great leap to monitor clinical pharmacodynamics. The investigators will collect vital signs, anesthestic depth (BIS=bispectral index, analgesia nociception index (ANI)), drug dosing (propofol, midazolam and alfentanil), and the MOAA/S (modified observer's assessment/alertness score) scores in patient who are receive routine general anesthesia under laryngeal mask or sedation for TEE (transesophageal echocardiography) examinations. Patient's consent will be obtained prior to enrollment. These recordings will be pooled into computer program for model construction. A novel model in the field of anesthesia was chosen and modified. As pioneers in this field in Taiwan, the investigators plan to perform a series of analysis using a novel model the investigators have built to look into detail on how drugs interact with each other. A safety boundary to avoid excessive respiratory depression can be drawn by the model. The main goal is to provide sedation that gives precision, patient comfort, rapid return of consciousness and safety based on the triple-drug response surface model.


Description:

This is an observational study of the routine clinical practice with no specific additional interventions required. Data acquisition (TEE patients) 1. After screening for eligible patients, protocol and study details will be thoroughly explained to them. 2. Strict fasting protocols were followed. A 22-gauge intravenous catheter was secured for drug administration. Each patient received standard anesthetic care monitors comprised of ECG (electrocardiography), oxygenation saturation (SpO2) and NIBP (non-invasive blood pressure). ECG and SpO2 (oxygenation saturation) were monitored continuously and NIBP were measured every 5 minutes. Supplemental oxygen (3~5 L/m) was given via nasal cannula, and SpO2 (oxygenation saturation) maintained above 90%. Intravenous bolus midazolam, alfentanil and propofol were given according to the anesthesiologist's preferences. Reference dosage range for midazolam is 0~5mg, alfentanil 0~1000mcg and propofol 0~60mg. Anesthetic depth was monitored with BIS and analgesia nociception index (ANI). BIS and ANI (analgesia nociception index) were for monitoring purposes only. 3. Instrumentation began after loss of response as evaluated by the anesthesiologist with the modified observer's assessment/alertness scale (MOAA/S). Intolerable desaturation was managed with mask ventilation or insertion of a nasal airway. An MOAA/S score lesser than 2 was considered loss of response (LOR) and fit for instrumentation. MOAA/S score would be recorded at induction, instrumentation, and emergence phase. Recordings will be added if patient had a MOAA/S score greater than 2. ANI (analgesia nociception index) and forehead BIS monitors will be used as an adjunct to assess anesthetic depth. Additional drug boluses were given if the patient expresses pain or excessive movements observed. 4. At the end of the procedure, the patient was observed until return of consciousness (MOAA/S > 5). The patients will be randomly divided into a model training group and a validation group after data acquisition by computer randomization using computer clock as seed. Data acquisition (Laryngeal mask patients) 1. After screening for eligible patients, protocol and study details will be thoroughly explained to them. 2. Strict fasting protocols were followed. A 22 or 20-gauge intravenous catheter was secured for drug administration. Each patient received standard anesthetic care monitors comprised of electrocardiography (ECG), SpO2 (oxygen saturation) and non-invasive blood pressure (NIBP). ECG and SpO2 (oxygen saturation) were monitored continuously and NIBP were measured every 5 minutes. Intravenous fentanyl and propofol were given according to the anesthesiologist's preferences. Reference dosage range for fentanyl 0~150mcg and propofol 0~200mg. Anesthetic depth was monitored with BIS and ANI (analgesia nociception index). BIS and ANI were for monitoring purposes only. 3. Instrumentation began after loss of response as evaluated by the anesthesiologist with the MOAA/S score. A MOAA/S score lesser than 2 was considered LOR (loss of response) and fit for instrumentation. After LMA placement, sevoflurane was started at 2~3% with a fresh gas flow at 1~6 L/m. The end-tidal sevoflurane concentration would be maintained above 0.7 minimal alveolar concentration to avoid awareness. MOAA/S score would be recorded at induction, instrumentation, during skin incision/closure and emergence phase. Recordings would be added if patient had a MOAA/S score greater than 2. ANI (analgesia nociception index) and forehead BIS monitors would be used as an adjunct to assess anesthetic depth. Additional drug boluses were given if the patient expresses pain or excessive movements observed. 4. At the end of the procedure, LMA was removed if the patient was breathing smoothly. The patient was observed until return of consciousness (MOAA/S > 5). The patients will be randomly divided into a model training group and a validation group after data acquisition by computer randomization using computer clock as seed. Model building, assessment and validation (both groups) 1. Collected data were fed to a pharmacokinetic simulation software (TIVA trainer Version 9.1) to calculate second-by-second plasma and effect-site drug concentration changes for all three drugs. The training patient group is used for model training. The bootstrap technique is used with 2000 iterations. Model fit was optimized using -2 Log likelihood (-2LL). 2. MOAA/S, BIS and ANI (analgesia nociception index) models would be constructed. 3. The results are validated with the validation patient data to confirm its clinical utility. Receiver operating characteristics (ROC) curve analysis is used to assess the quality of model prediction. ROC and area under the curve (AUC) will be compared between the training and validation group.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 25, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria: - Patients aged between 20 and 85 - Scheduled for transesophageal echocardiography (TEE) examination or surgery under laryngeal mask airway (LMA) depending on study arm. - American Society of Anesthesiologists (ASA) physical status I to III. Exclusion Criteria: TEE arm: - hearing impairment - neurologic or behavioral disorders - habitual sedative use - alcoholism - allergy to midazolam, alfentanil or propofol - resting room air SpO2 < 90%. - History of upper airway tumors LMA arm - hearing impairment - neurologic or behavioral disorders - habitual sedative use - alcoholism - allergy to sevoflurane, fentanyl or propofol, resting room air - SpO2 < 90% - poor dentition - non-fitting LMA - LMA insertion attempt greater than 2.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fentanyl
The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
Other:
Bispectral index (BIS) and analgesia nociception index (ANI)
After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
Drug:
alfentanil
The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
Propofol
The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
sevoflurane
The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
midazolam
The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.

Locations

Country Name City State
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

References & Publications (7)

[40 years of scientific-research work in medicine]. Patol Fiziol Eksp Ter. 1969 May-Jun;13(3):91-4. Russian. — View Citation

Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990 Aug;10(4):244-51. — View Citation

LaPierre CD, Johnson KB, Randall BR, Egan TD. A simulation study of common propofol and propofol-opioid dosing regimens for upper endoscopy: implications on the time course of recovery. Anesthesiology. 2012 Aug;117(2):252-62. — View Citation

Liou JY, Ting CK, Huang YY, Tsou MY. Previously published midazolam-alfentanil response surface model cannot predict patient response well in gastrointestinal endoscopy sedation. J Chin Med Assoc. 2016 Mar;79(3):146-51. doi: 10.1016/j.jcma.2015.11.002. Epub 2016 Jan 28. — View Citation

Liou JY, Ting CK, Mandell MS, Chang KY, Teng WN, Huang YY, Tsou MY. Predicting the Best Fit: A Comparison of Response Surface Models for Midazolam and Alfentanil Sedation in Procedures With Varying Stimulation. Anesth Analg. 2016 Aug;123(2):299-308. doi: 10.1213/ANE.0000000000001299. — View Citation

Liou JY, Ting CK, Teng WN, Mandell MS, Tsou MY. Adaptation of non-linear mixed amount with zero amount response surface model for analysis of concentration-dependent synergism and safety with midazolam, alfentanil, and propofol sedation. Br J Anaesth. 2018 Jun;120(6):1209-1218. doi: 10.1016/j.bja.2018.01.041. Epub 2018 Apr 17. — View Citation

Ting CK, Johnson KB, Teng WN, Synoid ND, Lapierre C, Yu L, Westenskow DR. Response surface model predictions of wake-up time during scoliosis surgery. Anesth Analg. 2014 Mar;118(3):546-53. doi: 10.1213/ANE.0000000000000094. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Observer's Assessment Alertness Scale(MOAA/S) score and changes between specified timepoints. Our study records these parameters on an observational basis. Anesthetic management remains identical regardless of patient participation or not.
Lack of patient movement during TEE(transesophageal echocardiography) or LMA (laryngeal mask airway) insertion is considered Modified Observer's Assessment Alertness Scale score(MOAA/S) < 1.
Return of consciousness is defined by a score of MOAA/S greater than 4. MOAA/S is a unitless score between 0 and 5 and is applicable in different anesthesia settings such as sedation for gastrointestinal endoscopy or awake craniotomies. Different procedures do not give different MOAA/S units.
The score is a part of anesthetic depth evaluation and the recordings are aggregated to perform fit in a mathematic model.
Specific events during the surgical or examination procedure (LMA insertion, TEE insertion, skin incision, skin closure, emergence, and patient movements).Reference time: TEE 15 minutes, LMA 2 hours.
Secondary BIS (bispectral index) value and changes between specified timepoints. Our study records these parameters on an observational basis. Anesthetic management remains identical regardless of patient participation or not. BIS values are recorded throughout the surgery or TEE examination to correlate with clinical observations. The recorded BIS reading is uniform and contains only a unitless number ranging from 0 to 100. Different procedures do not give different units. The value is a part of anesthetic depth evaluation and the recordings are aggregated to perform fit in a mathematic model. BIS will recorded continuously during the total anesthesia time (from induction to emergence). Reference time: TEE 15 minutes, LMA 2 hours..
Secondary ANI (Analgesia nociception index) and changes between specified timepoints. Our study records these parameters on an observational basis. Anesthetic management remains identical regardless of patient participation or not. ANI values are recorded throughout the surgery or TEE examination to correlate with clinical observations. The recorded ANI reading is uniform and contains only a unitless number ranging from 0 to 100. Different procedures do not give different units. The index is a part of anesthetic depth evaluation and the recordings are aggregated to perform fit in a mathematic model. ANI will recorded continuously during the total anesthesia time (from induction to emergence).Reference time: TEE 15 minutes, LMA 2 hours..
See also
  Status Clinical Trial Phase
Completed NCT02532998 - A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT00754871 - Pharmacodynamic Characterization of Dienogest Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT02306915 - PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants Phase 1
Completed NCT01158755 - Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study Phase 2
Completed NCT05005520 - Study of DTRI-031 in Healthy Volunteers Phase 1
Recruiting NCT03337581 - Pharmacodynamics and Pharmacokinetics of Dexmedetomidine in Pediatric Phase 4
Completed NCT03895229 - The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin Phase 1
Recruiting NCT05153837 - Effect of Oral Water in Healthy Volunteers on Cardiac Output, Regional Flow and Microcirculation in Healthy Volunteers N/A
Completed NCT01954589 - Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206 Phase 1
Withdrawn NCT01214122 - A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin Phase 1
Completed NCT02512575 - A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. Phase 1
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Recruiting NCT03161002 - Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor
Completed NCT05795192 - SB17170 Phase1 Trial in Healthy Volunteer Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT02308748 - Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Phase 1
Completed NCT05716854 - Electrophysiological Effects of Potential QT Prolonging Drugs Phase 1
Not yet recruiting NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II